Methotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis
Clinical and Experimental Dermatology · 2025
DOI: 10.1093/ced/llaf301 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical and Experimental Dermatology, 2025. Verfasst von Anton Olsson und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's Colleg…. Hauptthemen laut MEDLINE: CD4-Positive T-Lymphocytes, Cyclosporine, Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, National Institute for Health Research.
Abstract (Originalsprache)
Atopic dermatitis (AD) is a chronic dermatosis characterized by type-2 inflammatory responses, skin barrier anomalies and microbiome dysregulation. The variety of AD presentations necessitates a better understanding of the underlying disease mechanisms and the modulation of immune markers over a treatment course. Globally, the most used systemic therapies for moderate-to-severe AD are methotrexate (MTX) and ciclosporin (CyA). The TReatment of severe Atopic Eczema in children Trial (TREAT) was a randomized controlled trial (RCT) assessing the efficacy and safety of MTX and CyA. Peripheral blood samples from 18 TREAT participants were analysed in a longitudinal immunological study with a focus on cytokine-expressing CD4+ T cells. The analysis showed that both MTX and CyA were associated with a decreased percentage of interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells, corresponding to improved disease severity. Patients receiving MTX experienced a more sustained decrease in IL-4 expressing T cells, which corresponds to the longer-term improved disease control observed in the MTX arm.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Inflammation Biology and Cancer Immunology, Department of Inflammation Biology, School of Immunology and Microbial Sciences, King's College London, London, UK.
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK.
- Department of Paediatric Dermatology, St John's Institute of Dermatology, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.
- Medical Research Council Translational Immune Discovery Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
- Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
ORCID-Profile: Alan D Irvine, Carsten Flohr, Leonie S Taams
Förderung
- UK Medical Research Council
- National Institute for Health Research
Zitieren
APA
Olsson, A., Steel, K., Cooper, R., Jones, A. P., Chan, K. R., Ogg, G., Irvine, A. D., Flohr, C., & Taams, L. S. (2025). Methotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llaf301
Vancouver
Olsson A, Steel K, Cooper R, Jones AP, Chan KR, Ogg G, et al. Methotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis. Clinical and Experimental Dermatology. 2025. doi:10.1093/ced/llaf301
BibTeX
@article{Olsson2025,
author = {Olsson, Anton and Steel, Kathryn and Cooper, Rachael and Jones, Ashley P and Chan, Kaitlyn R and Ogg, Graham and Irvine, Alan D and Flohr, Carsten and Taams, Leonie S},
title = {Methotrexate and ciclosporin both reduce levels of circulating interleukin (IL)-4 and IL-13 expressing CD4+ memory T cells in childhood atopic dermatitis},
journal = {Clinical and Experimental Dermatology},
year = {2025},
doi = {10.1093/ced/llaf301}
}
EUVIMED